Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

$8.55

-0.30 (-3.39%)

(As of 09/27/2024 ET)

Terns Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 5 Analyst Ratings

Sell
0

Hold
1

Buy
4

Based on 5 Wall Street analysts who have issued ratings for Terns Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a hold rating, and 4 have given a buy rating for TERN.

Consensus Price Target

$15.90
85.96% Upside

According to the 5 analysts' twelve-month price targets for Terns Pharmaceuticals, the average price target is $15.90. The highest price target for TERN is $26.00, while the lowest price target for TERN is $5.50. The average price target represents a forecasted upside of 85.96% from the current price of $8.55.

Get the Latest News and Ratings for TERN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Terns Pharmaceuticals and its competitors.

TERN Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.90	$13.50	$14.50	$16.11
Forecasted Upside	85.96% Upside	77.17% Upside	111.68% Upside	220.30% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

TERN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TERN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Terns Pharmaceuticals Stock vs. The Competition

Type	Terns Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	85.96% Upside	818.50% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent TERN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	BMO Capital Markets 4 of 5 stars	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $26.00	+191.81%
9/10/2024	JMP Securities 2 of 5 stars	Boost Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $20.00	+119.30%
5/14/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Neutral ➝ Neutral	$5.50	-6.62%
3/27/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$19.00 ➝ $18.00	+187.54%
11/27/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$17.00 ➝ $10.00	+164.55%
8/9/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$10.00 ➝ $11.00	+82.42%
Get the Latest News and Ratings for TERN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/8/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$23.00	+242.26%
6/7/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00	+54.77%
12/20/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$9.00 ➝ $14.00	+61.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:18 PM ET.

TERN Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Terns Pharmaceuticals is $15.90, with a high forecast of $26.00 and a low forecast of $5.50.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TERN shares.
: According to analysts, Terns Pharmaceuticals's stock has a predicted upside of 85.96% based on their 12-month stock forecasts.
: Terns Pharmaceuticals has been rated by research analysts at BMO Capital Markets, and JMP Securities in the past 90 days.
: Analysts like Terns Pharmaceuticals more than other "medical" companies. The consensus rating score for Terns Pharmaceuticals is 2.80 while the average consensus rating score for "medical" companies is 2.78. Learn more on how TERN compares to other companies.